Abstract: An improved process is described for the purification of ropinirole hydrochloride. The process includes (i) dissolving ropinirole hydrochloride in water; (ii) treating the solution obtained in step (i) with sodium dithionate and charcoal; (iii) treating the filtrate obtained in step (ii) with water immiscible solvent and base and isolating the free base; and (iv) treating the free base obtained in step (iii) with ethanolic HCl to give ropinirole hydrochloride.

Abstract: The present invention provides an improved process for the purification of ropinirole hydrochloride. The process includes (i) treating ropinirole hydrochloride with sodium dithionate and charcoal in suitable alcoholic solvent; (ii) triturating the ropinirole hydrochloride obtained in step (i) with ethanol; (iii) reacting the triturated solid with base in water immiscible solvent and isolating the free base; and (iv) treating the free base obtained in step (iii) with ethanolic HCl to give ropinirole hydrochloride.

Abstract: An improved process is described for the purification of ropinirole hydrochloride. The process includes (i) dissolving ropinirole hydrochloride in water; (ii) treating the solution obtained in step (i) with sodium dithionate and charcoal; (iii) treating the filtrate obtained in step (ii) with water immiscible solvent and base and isolating the free base; and (iv) treating the free base obtained in step (iii) with ethanolic HCl to give ropinirole hydrochloride.

Abstract: The present invention relates to an improved process for the preparation of Entacapone of formula (I) comprising a step of, condensation of 3,4-dihydroxy-5-nitrobenzaldehyde of formula (II) with N,N-diethylcyanoacetamide of formula (III) in the presence of two component solvent system, a catalyst and optionally a phase transfer catalyst to give Entacapone of formula (I).

Abstract: The present invention relates to an improved process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1,2,3,4-tetrahydroquinolin-2-one (Aripiprazole) having dimer impurity less than 0.15%, particularly, the present invention relates to an improved process for the preparation of 7-(4-chlorobutoxy)-3,4-dihydrocarbostyril of formula (I) having dimer impurity less than 0.5% which includes a step of reacting 7-hydroxy-tetrahydroquinolinone of formula (III) with 1-bromo-4-chlorobutane in the presence of a base in a solvent.

Abstract: The present invention provides an improved process for the purification of ropinirole hydrochloride. The process includes (i) treating ropinirole hydrochloride with sodium dithionate and charcoal in suitable alcoholic solvent; (ii) triturating the ropinirole hydrochloride obtained in step (i) with ethanol; (iii) reacting the triturated solid with base in water immiscible solvent and isolating the free base; and (iv) treating the free base obtained in step (iii) with ethanolic HCl to give ropinirole hydrochloride.

Abstract: The present invention relates to a process for the purification of Sucralose of formula (I) which comprises acetylation of substantially impure Sucralose to its penultimate intermediate 4,1?,6?-trichloro-4,1?,6?-trideoxy galactosucrose penta-acetate (TOPSA) of formula (VI) followed by purification of TOPSA and then deacetylation of purified TOPSA.

Abstract: A process for the preparation of Irbesartan of formula (I) using the step of, reacting biphenyl derivative of formula (VIa) wherein R represents a group selected from —CONH2 or compound of formula wherein X represents H or C1-4 alkyl, preferably methyl; or any other such group which can be converted to cyano group, with 1-veleramido cyclopentane carboxylic acid of formula (V) in the presence of an acid in an organic solvent to give biphenyl derivative of formula (VIIa) wherein R has the same meaning as mentioned hereinabove.

Abstract: A process for the preparation of Pentosan polysulfate sodium comprising a step of purifying depolymerized crude Pentosan polysulfate sodium by filtration through NF membrane system.

Abstract: The present invention relates to an improved process for preparation of Rivastigmine of formula (I) or pharmaceutically acceptable salts thereof comprising a step of N-methylation of compound of formula (III), wherein R1=R2=H or R1=H and R2=CH3 or an acid addition salt thereof, using paraformaldehyde in the presence of Raney Nickel and hydrogen in a suitable solvent to obtain compound of formula (II).

Abstract: A process for the preparation of cefoxitin of formula (I) The process includes treating the compound of formula (II) with a halogenating agent in an organic solvent, followed by treatment with alkali/alkaline earth metal methoxide at a temperature in the range of ?100° C. to 0° C. The product formed is then isolated as an organic amine salt of the formula (III), The salt of formula (III) is treated with a base in the presence of solvent at a temperature in the range of ?75 to 10° C., the product formed is isolated as an organic amine salt of the formula (IV) The compound of formula (IV) is carbamoylated with isocyanate of formula (V) RNCO??(V) in the presence of a solvent at a temperature in the range of ?60° C. to 10° C., and isolating to get cefoxitin of the formula (I).

Abstract: A process for the preparation of Irbesartan of formula (I) using the steps of: (i) reacting 4? aminomethyl-2-cyano biphenyl of formula (VI) with 1-veleramido cyclopentane carboxylic acid of formula (V) in an organic solvent and in the presence of an acid, without activating the —COOH group of compound of formula (V) to give 1-(2?cyanobiphenyl-4-yl-methylaminocarbonyl)-1-pentanoylamino cyclopentane of formula (VII). converting the compound of formula (VII) obtained in step (i) to Irbesartan of formula (I) by reacting the compound of the formula (VII) with tributyl tin azide in o-xylene to give Irbesartan of formula (I).

Abstract: The present invention relates to an improved process for the preparation of Sucralose having purity of at least 99.6% comprising steps of (i) dissolving substantially impure Sucralose in water (ii) treating the solution obtained in step (i) with a partially water immiscible solvent (iii) washing the said solvent phase obtained in step (ii) with an amount of water sufficient to remove polar impurities (iv) crystallizing the product from partially water immiscible solvent (v) recrystallizing the solid obtained in step (iv) from water.

Abstract: The invention relates to commercially viable process for the preparation of Rosuvastatin by an early introduction of the correct absolute stereochemistry at C-5 (S) of Rosuvastatin side chain followed by regioselective chain extension using novel side chain building blocks. It is yet another object of the invention is to provide novel intermediates that may be used for the preparation of Rosuvastatin. Formula (I).

Abstract: The present invention provides a novel process for preparation of bisphosphonic acid derivatives or pharmaceutical acceptable salt thereof, by reacting carboxylic acid having structural formula (II) with phosphorous acid and a halophosphorous compound, wherein halophosphorous compound is selected from the group comprising of PCl3, PCl5, POCl3, PBr3, POBr3, and PBr5 in presence of diphenyl ether.

Abstract: The invention relates to commercially viable process for the preparation of Rosuvastatin by an early introduction of correct absolute stereochemistry at C-5 (S) of Rosuvastatin side chain followed by regioselective chain extension using novel side chain building blocks and less expensive reagents. It is yet another object of the invention is to provide novel intermediates that may be used for the preparation of Calcium salt of Rosuvastatin.Formula (I).

Abstract: A process for the preparation of cephalosporin antibiotic of the formula (I) which comprises: (i) activating the compound of formula (III) as acid halide in an organic solvent (ii) treating the reaction mass obtained from step (i) with water (iii) separating the organic layer containing the reactive derivative of formula (III) and condensing it with 7-amino cephalosporin derivative by maintaining the pH in the range 5.0-10.0 using an inorganic base of the formula (XV), and iv) cyclizing the compound of formula (XVI) with thiourea in the presence of solvent and salt of organic or inorganic acid at a temperature in the range of ?50 to +50° C. to produce compound of formula (I).

Abstract: The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable salts wherein, R is

Abstract: The present invention relates to an improved process for preparation of Rivastigmine of formula (I) or pharmaceutically acceptable salts thereof comprising a step of N-methylation of compound of formula (III), wherein R1=R2=H or R1=H and R2=CH3 or an acid addition salt thereof, using paraformaldehyde in the presence of Raney Nickel and hydrogen in a suitable solvent to obtain compound of formula (II).

Abstract: A process for the preparation of 3-methylcepham-4-carboxylate of the formula (I). wherein R2 and R3 may be same or different and represent hydrogen, halogen, amino, alkyl, phenacetamido, substituted acetamido, phthalimido with a proviso that both R2 and R3 are not NH2, phenacetamido, phthalimido and the like; R1 represents a lower alkyl, p-methoxybenzyl, p-nitrobenzyl, o-nitrobenzyl, o-methoxybenzyl, o-chlorobenzyl or diphenylmethyl group, or a suitable ester residue which can be deprotected at a latter stage, L represents a leaving group; which comprises cyclizing the compound of formula (III) using a cyclizing agent in the presence of organic or inorganic nitrites and a solvent at a temperature in the range of ?40° C. to +60° C. to obtain compound of formula (I).